Carbon dots have antitumor action as monotherapy or combination therapy.

Carbon dots have antitumor action as monotherapy or combination therapy. Drug Discov Ther. 2019;13(2):114-117 Authors: Xia J, Kawamura Y, Suehiro T, Chen Y, Sato K Abstract Carbon dots prepared from different sources have been widely studied in various medical applications. Those dots have been reported to be able to inhibit the proliferation of cancer cells, such as prostate cancer cells. The current study used carbon dots prepared from red beans to determine their effect on 16 cell lines including liver cancer cells, pancreatic cancer cells, intrahepatic cholangiocarcinoma cells, and colorectal adenocarcinoma cells. In a cellular viability experiment, carbon dots were found suppress cancer cell viability in a time- and dose-dependent manner. In a cell migration experiment, cancer cells treated with carbon dots had less ability to heal, suggesting that carbon dots inhibit cell migration. In another cellular viability experiment, a combination of carbon dots and doxorubicin resulted in greater inhibition than cells treated with either therapy alone. These findings suggest that carbon dots could be an alternative and complementary medicine for the treatment of cancers. PMID: 31080202 [PubMed - in process]
Source: Drug Discoveries and Therapeutics - Category: Drugs & Pharmacology Tags: Drug Discov Ther Source Type: research

Related Links:

Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part BAuthor(s): Yanhua Liu, Yang Li, Shanshan Dong, Lu Han, Ruixin Guo, Yourong Fu, Shenghu Zhang, Jianqiu Chen
Source: Journal of Hazardous Materials - Category: Environmental Health Source Type: research
Authors: Musio F Abstract INTRODUCTION: Anemia has and will continue to be a central theme in medicine particularly as clinicians are treating a burgeoning population of complex multi-organ system processes. As a result of multiple randomized controlled trials (RCTs), meta-analyses, and societal recommendations overly restrictive paradigms and under-administration of erythropoiesis stimulating agents (ESAs) have likely been followed by clinicians among all specialties. AREAS COVERED: A review of anemia in the context of chronic kidney disease, hematologic malignancies and cancer is presented with focus on the e...
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
Publication date: January 2021Source: Urology Case Reports, Volume 34Author(s): Nina Al-Saadi, Safa Al-Musawi, Yousuf Khan, Daben Dawam
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
Authors: Matti B, Zargar-Shoshtari K Abstract Prostate cancer represents a significant health burden worldwide. The cancer incidence had substantially increased since the introduction of prostate specific antigen (PSA) in cancer screening. This had led to considerable debates among health professionals and epidemiologists, since PSA as a screening tool seemed to be far from perfect. In New Zealand, the controversy was quite prominent in the last three decades, with some advocating the benefits of screening, while others concerned regarding the risk of harms. With the absence of an organised screening programme and ...
Source: New Zealand Medical Journal - Category: General Medicine Tags: N Z Med J Source Type: research
CONCLUSION: This study found that childhood cancer survivors in New Zealand had a high prevalence of developmental dental abnormalities and it identified potential risk factors related to their cancer treatment. Inequitable access to oral rehabilitation for this patient group argues for a mechanism for consistent improved access to publicly funded dental care across district health boards in New Zealand. PMID: 33032302 [PubMed - in process]
Source: New Zealand Medical Journal - Category: General Medicine Tags: N Z Med J Source Type: research
Authors: Zarrabi A, Mark S PMID: 33032299 [PubMed - in process]
Source: New Zealand Medical Journal - Category: General Medicine Tags: N Z Med J Source Type: research
Authors: Peng C, Cohen DJ Abstract INTRODUCTION: Esophageal squamous cancer remains an important cause of mortality worldwide with two new immunotherapy drugs recently approved for metastatic disease. AREAS COVERED: The authors review the epidemiology and genomics of esophageal squamous cell carcinoma. They also examine prior trials involving targeted agents under investigation as well immunotherapies that have been approved and novel combinations. EXPERT OPINION: Great advances have been made in characterizing the molecular changes in esophageal carcinoma. However, relatively few drugs have shown benefit i...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
This article summarizes the rationale for, and development of CDK inhibitors in melanoma, with their evolution from pan-CDK inhibitors to highly specific agents, throughout clinical trials and finally their potential future use. EXPERT OPINION: Whilst CDK inhibitors have been practice changing in breast cancer management, their efficacy is yet to be proven in melanoma. Combination with BRAF/MEK inhibitors has been hindered by dose-limiting toxicities, but their role may yet to be found within the spectrum of biomarker-derived personalized melanoma management. The effect that CDK inhibitors can have as an adjunct to imm...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
CONCLUSIONS: The cfDNA level in the CSF can be used as a supplemental marker for diagnosing LMS in hematologic malignancy patients. PMID: 33029963 [PubMed]
Source: Journal of Clinical Neurology - Category: Neurology Tags: J Clin Neurol Source Type: research
We wanted to determine whether allogeneic haematopoietic stem cell transplantation (HSCT) may result in long-term survival in patients with solid cancer. HSCT was performed in 61 patients with solid cancer: metastatic renal carcinoma (n=22), cholangiocarcinoma (n=17), colon carcinoma (n=15), prostate cancer (n=3), pancreatic adenocarcinoma (n=3), or breast cancer (n=1). Liver transplantation was performed for tumour debulking in 18 patients. Median age was 56 years (range 28‒77). Donors were either HLA-identical siblings (n=29) or unrelated (n=32).
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
More News: Adenocarcinoma | Alternative and Complementary Therapies | Bile Duct Cancer | Cancer | Cancer & Oncology | Cholangiocarcinoma | Colorectal Cancer | Complementary Medicine | Drugs & Pharmacology | Liver | Pancreas | Pancreatic Cancer | Prostate Cancer | Study | Urology & Nephrology